Filing Details
- Accession Number:
- 0001209191-15-084824
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-12-11 19:00:39
- Reporting Period:
- 2015-12-09
- Filing Date:
- 2015-12-11
- Accepted Time:
- 2015-12-11 19:00:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1411158 | Anacor Pharmaceuticals Inc. | ANAC | Pharmaceutical Preparations (2834) | 251854385 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1430426 | P Vincent Ippolito | C/O Anacor Pharmaceuticals, Inc. 1020 East Meadow Circle Palo Alto CA 94303 | Evp & Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-12-09 | 20,000 | $19.96 | 91,840 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-12-09 | 17,270 | $107.85 | 74,570 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-12-09 | 2,730 | $108.22 | 71,840 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2015-12-09 | 20,000 | $0.00 | 20,000 | $19.96 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 81,000 | 2024-03-06 | No | 4 | M | Direct |
Footnotes
- Includes shares purchased in 2015 pursuant to the Issuer's ESPP.
- This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.12 to $108.11, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.12 to $108.80, inclusive.
- The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was February 28, 2014.
Billionaire Hedge Funds
